Statutory Committee inquiries
The Statutory Committee will meet at the Royal Pharmaceutical Society of Great Britain, 1 Lambeth High Street, London SE1, at 9.30am on Monday 20 March, Tuesday 21 March, Wednesday 22 March and Thursday 23 March 2006 to hear the following inquiries:
Monday 20 March
1. The committee will resume its inquiry into a complaint by the Council of
the Society against John Brian Price (registration number 54597) which alleges
that a failure to provide the best possible health care to a patient; a failure
to adhere to accepted standards of professional conduct and engaging in behaviour
likely to undermine public confidence in the profession; and the use of a
SCENAR [self-controlled energo neuro adaptive regulation] device, despite
having no training or accreditation in the use of complementary therapies
for the treatment of facial infections, may amount to misconduct.
2. The committee will resume its inquiry into a complaint by the Council of
the Society against Maria Mariscal Navarro (registration number 1078456) and
Andrew Murdock (registration number 73499) which alleges that a labelling error
and failure to deal appropriately with a complaint concerning the error, may
amount to misconduct.
Tuesday 21 March
3. An inquiry into a complaint by the Council of the Society against Michael
Turner (registration number 67819) which alleges that the unlawful possession
of Controlled Drugs; the possession of quantities of prescription-only medicines
at his home; a failure to make entries in the Controlled Drugs register in
respect of methadone and amphetamine purchases and supplies; the unlawful
supplies of methadone and/or diazepam; and providing false information to
police officers, may amount to misconduct. The committee will also consider
convictions for various driving offences; two counts of the supply of class
A Controlled Drugs contrary to Section 4(1) of the Misuse of Drugs Act 1971;
three counts of the supply of Class C Controlled Drugs contrary to section
4(1) of the Misuse of Drugs Act 1971; and one count of possession of a Class
B Controlled Drug contrary to section 5 (3) of the Misuse of Drugs Act 1971.
Wednesday 22 March
4. The committee will deliver the determination of the inquiry into a complaint
by the Council of the Society against Maysa Jibreel Al-Natsheh (registration
number 90768) and Preston Park Chemists Ltd (identification number 1087052)
which alleged that a failure to ensure that the pharmacist in charge had
the requisite knowledge, skills and fitness to perform the work delegated
to him; a failure to ensure that he was sufficiently competent in English;
a failure to ensure that he was properly informed of the professional duties
he was expected to undertake; a failure to supervise and support the pharmacist
in charge; and a failure to exercise proper control over the business, may
have amounted to misconduct.
5. The committee will resume its inquiry a complaint by the Council of the
Society against Derek Michael Phillips (registration number 75766) which alleges
that discrepancies in stocks of Viagra 50mg and 100mg; breaches of Regulation
19 of the Misuse of Drugs Regulations; breaches of the Misuse of Drugs (Safe
Custody) Regulations; a failure to deal appropriately with Controlled Drugs
(failure to segregate patient returns and date-expired stock); the supply of
sildenafil without a valid prescription; breaches of Regulation 6 of the Medicines
(Sale and Supply) (Miscellaneous Provisions) Regulations 1980; and the condition
of the pharmacy notwithstanding a warning from the Society inspector, may amount
to misconduct.
Thursday 23 March
6. The committee will resume the inquiry into a complaint by the Council of
the Society against John Joseph George Barnes (registration number 62087)
which alleges that a dispensing error; a failure to contact the prescriber
for clarification; the dismissive response to the error; a failure to keep
an accurate record in the patient medication record; and a failure to record
the error, may amount to misconduct.
David Gomez
Secretary to the Statutory Committee |
The
Pharmaceutical Journal